Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism
- 18 February 2011
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 62 (1) , 41-57
- https://doi.org/10.1146/annurev-med-062209-095159
Abstract
The last decade has seen the evaluation of several new oral anticoagulants that directly target thrombin or activated factor X (FXa). All demonstrate a rapid onset of action, a low potential for fo...Keywords
This publication has 37 references indexed in Scilit:
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in DevelopmentClinical Pharmacokinetics, 2009
- Pharmacology and Management of the Vitamin K AntagonistsChest, 2008
- Comparison of Outcomes Among Patients Randomized to Warfarin Therapy According to Anticoagulant ControlArchives of internal medicine (1960), 2007
- Ximelagatran/melagatran against conventional anticoagulation: A meta-analysis based on 22,639 patientsInternational Journal of Cardiology, 2007
- Comparison of Fondaparinux and Enoxaparin in Acute Coronary SyndromesNew England Journal of Medicine, 2006
- Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic SurgeryA Meta-analysis of 4 Randomized Double-blind StudiesArchives of internal medicine (1960), 2002
- Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' dataThe Lancet, 2002
- Why Do Patients With Atrial Fibrillation Not Receive Warfarin?Archives of internal medicine (1960), 2000